Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

RIGL vs DMAC: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

RIGL Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 10–0 Matrix Metrics)

RIGL Overall Winner 6-Pillar Tally: RIGL 5 – 1 DMAC Matrix Metrics: RIGL 10 – 0 DMAC

As of Nov 16, 2026, Rigel Pharmaceuticals Inc. (New) (RIGL) is the stronger overall head-to-head candidate over DiaMedica Therapeutics Inc. (DMAC) in the Tradestie Institutional Equity Comparison Engine, winning 10–0 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). RIGL carries a Unified Composite Score of 59.9/100 (HOLD) at $43.73 (9.3x Forward P/E, 26.3% operating margin), whereas DMAC carries 46.3/100 (HOLD) at $8.41 (N/M Forward P/E, 0.0% operating margin).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About RIGL vs DMAC
RIGL NASDAQ Head-to-Head Winner
Rigel Pharmaceuticals Inc. (New)
Pharmaceutical Preparations
$43.73
-1.64% 1D
Market Cap $860.3M
TTM Revenue $288M
Forward P/E 9.3x
Beta / 30D Vol 1.05β · 74% Vol
Unified Composite Score
59.9 / 100 HOLD
Tech 48.0 Fund 58.0 Flow 68.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 43
RSI-14: 42.6 · SMA20: $47.42 · SMA50: $47.34
DMAC NASDAQ
DiaMedica Therapeutics Inc. Common Stock
Pharmaceutical Preparations
$8.41
-4.27% 1D
Market Cap $503.1M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.74β · 98% Vol
Unified Composite Score
46.3 / 100 HOLD
Tech 30.0 Fund 51.0 Flow 65.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 45
RSI-14: 44.7 · SMA20: $9.24 · SMA50: $8.24

6-Pillar Scorecard Institutional Category Breakdown (RIGL 5 – 1 DMAC)

Columns: Metric · RIGL · DMAC
1. Valuation Multiples RIGL
Forward P/E 9.3x N/M
Trailing P/E 2.8x N/M
PEG Ratio N/M N/M
EV / Revenue 2.9x N/M
2. Growth & Scale RIGL
Revenue Growth (YoY) +16.5% +0.0%
Earnings Growth (YoY) -55.5% +0.0%
TTM Revenue (USD) $288M N/A
Market Cap $860.3M $503.1M
3. Profitability & Quality RIGL
Gross Margin 70.7% N/A
Operating Margin 26.3% 0.0%
Net Profit Margin 106.6% 0.0%
Return on Equity (ROE) 109.2% -114.6%
4. Balance Sheet & Cash Flow RIGL
Cash Generation (TTM) $19M -$32M
Cash Flow Margin 6.7% N/A
Net Cash / Leverage $39M Net Cash $4.9M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning DMAC
Options Structure Phase CONSOLIDATION SURGE
Current IV / %ile 61.2% (4th %ile) 106.3% (14th %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Neutral NEUTRAL · Neutral
6. R&D & Supply-Chain Moat RIGL
OpEx & R&D Intensity 44.4% of Rev ($128M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat High-Margin Pricing Power Moat Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: RIGL (10) vs DMAC (0)
Institutional Metric RIGL DMAC Criterion Row Edge
Market Capitalization
Scale
$860.3M $503.1M Larger Scale RIGL
Trailing P/E Ratio
Valuation
2.8x N/M Lower Multiple RIGL
Forward P/E Ratio
Valuation
9.3x N/M Lower Multiple RIGL
Revenue Growth (YoY)
Growth
+16.5% +0.0% Higher Growth RIGL
Operating Margin (TTM)
Profitability
26.3% 0.0% Higher Margin RIGL
Net Profit Margin
Profitability
106.6% 0.0% Higher Margin RIGL
Return on Equity (ROE)
Capital Efficiency
109.2% -114.6% Higher ROE RIGL
52-Week Range Position
Momentum
68% ($25–$53) 55% ($5–$11) Stronger Trend RIGL
Beta / 30D Volatility
Risk Regime
1.05β · 74% Vol 1.74β · 98% Vol Lower Realized Risk RIGL
Unified Institutional Score
Composite Signal
59.9 / 100 (HOLD) 46.3 / 100 (HOLD) Higher Composite RIGL
Trailing 12M Revenue (USD)
Operating Scale
$288M N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
70.7% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 2.9x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$19M ($39M Net Cash) -$32M ($4.9M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon DMAC +16.03 pp
RIGL: -4.87% · DMAC: +11.16%
3M Horizon DMAC +27.06 pp
RIGL: +0.25% · DMAC: +27.31%
6M Horizon RIGL +4.7 pp
RIGL: +52.85% · DMAC: +48.15%
1Y Horizon DMAC +45.61 pp
RIGL: +9.65% · DMAC: +55.26%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period RIGL Revenue DMAC Revenue RIGL Op. Margin DMAC Op. Margin Margin Leader
FY2018 $40M $0M -163.3% -1352.2% RIGL
FY2019 $60M N/A -116.5% N/A RIGL
FY2020 $110M N/A -26.7% N/A RIGL
FY2021 $150M N/A -8.4% N/A RIGL
FY2022 $120M N/A -46.2% N/A RIGL
FY2023 $120M N/A -17.5% N/A RIGL
FY2024 $180M N/A 13.5% N/A RIGL
FY2025 $290M N/A 42.6% N/A RIGL

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
RIGL CONSOLIDATION
91d in phase · OBV NEUTRAL
Current IV 61.2%
IV Percentile 4th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact RIGL Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
DMAC SURGE
8d in phase · OBV NEUTRAL
Current IV 106.3%
IV Percentile 14th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact DMAC Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
RIGL Moat Profile High-Margin Pricing Power Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $860.3M market capitalization and 26.3% operating margin.
OpEx & R&D Reinvestment 44.4% of Rev ($128M)
90D Engineering Disclosures 0 Published
DMAC Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $503.1M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ RIGL vs DMAC Key Questions & Quantitative Answers

As of Nov 16, 2026, Rigel Pharmaceuticals Inc. (New) (RIGL) is the stronger overall head-to-head candidate over DiaMedica Therapeutics Inc. (DMAC) in the Tradestie Institutional Equity Comparison Engine, winning 10–0 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). RIGL carries a Unified Composite Score of 59.9/100 (HOLD) at $43.73 (9.3x Forward P/E, 26.3% operating margin), whereas DMAC carries 46.3/100 (HOLD) at $8.41 (N/M Forward P/E, 0.0% operating margin). Technically, RIGL sits in a Neutral phase (RSI 42.6, CONSOLIDATION options structure) and DMAC sits in a Neutral phase (RSI 44.7, SURGE options structure).

RIGL leads the Growth & Scale pillar: RIGL posts +16.5% YoY revenue growth and -55.5% YoY earnings growth on $288M TTM revenue (70.7% gross margin, 26.3% operating margin), compared with DMAC at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), RIGL cumulative revenue shifted +625.0% while DMAC shifted N/A. In operating R&D and SG&A reinvestment, RIGL deploys 44.4% of Rev ($128M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for DMAC.

RIGL screens cheaper on headline valuation multiples. RIGL trades at 9.3x Forward P/E, 2.8x Trailing P/E, N/M PEG, and 2.9x EV/Revenue (6.7% FCF margin), whereas DMAC trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against RIGL (109.2% ROE) versus DMAC (-114.6% ROE) capital efficiency.

In options market volatility and institutional positioning, RIGL carries 61.2% implied volatility (4th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (1.05β · 74% Vol realized risk). By comparison, DMAC carries 106.3% implied volatility (14th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a SURGE options structure phase (1.74β · 98% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.